Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib: Empfehlungen einer interdisziplinären Expertengruppe = Prevention and management of cardiovascular diseases during treatment with the tyrosine kinase inhibitor nilotinib : recommendations of an interdisciplinary expert group
Background Due to the increasing use of targeted substances for the treatment of cancer diseases, hematologists and oncologists are increasingly confronted with unexpected side effects. Severe long-term side effects are of special importance for patients with a good prognosis and require an interdis...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Deutsch Englisch |
| Veröffentlicht: |
August 2015
|
| In: |
Der Onkologe
Year: 2015, Jahrgang: 21, Heft: 8, Pages: 724-731 |
| ISSN: | 1433-0415 |
| DOI: | 10.1007/s00761-015-2990-5 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00761-015-2990-5 Verlag, Volltext: http://link.springer.com/article/10.1007/s00761-015-2990-5 
|
| Verfasserangaben: | A. Kiani, P. Kuhlencordt, A. Hochhaus, H. Tesch, S. Saussele, P. Le Coutre |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1552519821 | ||
| 003 | DE-627 | ||
| 005 | 20230426141213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170130s2015 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00761-015-2990-5 |2 doi | |
| 035 | |a (DE-627)1552519821 | ||
| 035 | |a (DE-576)482519827 | ||
| 035 | |a (DE-599)BSZ482519827 | ||
| 035 | |a (OCoLC)1340956021 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a ger |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kiani, Alexander |e VerfasserIn |0 (DE-588)1124425195 |0 (DE-627)878114858 |0 (DE-576)482519711 |4 aut | |
| 245 | 1 | 0 | |a Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib |b Empfehlungen einer interdisziplinären Expertengruppe = Prevention and management of cardiovascular diseases during treatment with the tyrosine kinase inhibitor nilotinib : recommendations of an interdisciplinary expert group |c A. Kiani, P. Kuhlencordt, A. Hochhaus, H. Tesch, S. Saussele, P. Le Coutre |
| 246 | 3 | 1 | |a Prevention and management of cardiovascular diseases during treatment with the tyrosine kinase inhibitor nilotinib |b recommendations of an interdisciplinary expert group |
| 264 | 1 | |c August 2015 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.01.2017 | ||
| 520 | |a Background Due to the increasing use of targeted substances for the treatment of cancer diseases, hematologists and oncologists are increasingly confronted with unexpected side effects. Severe long-term side effects are of special importance for patients with a good prognosis and require an interdisciplinary approach. One example is the tyrosine kinase inhibitor nilotinib, which represents an important treatment option for patients with chronic myeloid leukemia. Generally, nilotinib is well tolerated but recent reports have suggested that nilotinib is associated with an increased cardiovascular risk. Methods This article presents the recommendations of an interdisciplinary expert group of hematologists and vascular specialists with respect to the prevention and treatment of cardiovascular diseases during treatment of patients with nilotinib. Results and conclusion Prior to the initiation of treatment all patients should be stratified with respect to their individual cardiovascular risk. Patients of the highest risk category should preferably be treated with an alternative tyrosine kinase inhibitor, if comparable treatment options are available. During treatment with nilotinib all patients should be regularly monitored, with the content and frequency of the monitoring tailored to the individual cardiovascular risk. Cardiovascular risk factors should be meticulously treated and special attention should be paid to early signs of progressive atherosclerosis. An algorithm is suggested for the management of patients with signs of progressive atherosclerosis or occurrence of a cardiovascular event during treatment with nilotinib. | ||
| 650 | 4 | |a Cardiovascular event | |
| 650 | 4 | |a Cardiovascular risk | |
| 650 | 4 | |a Kardiovaskuläres Ereignis | |
| 650 | 4 | |a Kardiovaskuläres Risiko | |
| 650 | 4 | |a Langzeittoxizitäten | |
| 650 | 4 | |a Long-term side effects | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Peripheral arterial occlusive disease | |
| 650 | 4 | |a Periphere arterielle Verschlusskrankheit | |
| 650 | 4 | |a Tyrosine kinase inhibitor | |
| 650 | 4 | |a Tyrosinkinaseinhibitor | |
| 700 | 1 | |a Saußele, Susanne |d 1968- |e VerfasserIn |0 (DE-588)115839860 |0 (DE-627)69162786X |0 (DE-576)29010694X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Onkologe |d Berlin : Springer, 1996 |g 21(2015), 8, Seite 724-731 |h Online-Ressource |w (DE-627)254638546 |w (DE-600)1462966-5 |w (DE-576)074531522 |x 1433-0415 |7 nnas |a Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib Empfehlungen einer interdisziplinären Expertengruppe = Prevention and management of cardiovascular diseases during treatment with the tyrosine kinase inhibitor nilotinib : recommendations of an interdisciplinary expert group |
| 773 | 1 | 8 | |g volume:21 |g year:2015 |g number:8 |g pages:724-731 |g extent:8 |a Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib Empfehlungen einer interdisziplinären Expertengruppe = Prevention and management of cardiovascular diseases during treatment with the tyrosine kinase inhibitor nilotinib : recommendations of an interdisciplinary expert group |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00761-015-2990-5 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://link.springer.com/article/10.1007/s00761-015-2990-5 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170130 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 115839860 |a Saußele, Susanne |m 115839860:Saußele, Susanne |d 60000 |d 61200 |e 60000PS115839860 |e 61200PS115839860 |k 0/60000/ |k 1/60000/61200/ |p 5 | ||
| 999 | |a KXP-PPN1552519821 |e 2952365083 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1552519821"],"doi":["10.1007/s00761-015-2990-5"]},"recId":"1552519821","person":[{"role":"aut","family":"Kiani","given":"Alexander","display":"Kiani, Alexander"},{"role":"aut","family":"Saußele","given":"Susanne","display":"Saußele, Susanne"}],"titleTranslated":[{"translated":"Prevention and management of cardiovascular diseases during treatment with the tyrosine kinase inhibitor nilotinib"}],"note":["Gesehen am 30.01.2017"],"origin":[{"dateIssuedDisp":"August 2015","dateIssuedKey":"2015"}],"language":["ger","eng"],"relHost":[{"part":{"text":"21(2015), 8, Seite 724-731","volume":"21","issue":"8","pages":"724-731","year":"2015","extent":"8"},"language":["ger"],"origin":[{"dateIssuedKey":"1996","publisherPlace":"Berlin ; Heidelberg ; New York","dateIssuedDisp":"1996-2022","publisher":"Springer"}],"pubHistory":["Nachgewiesen 2.1996,3 - Volume 28, issue 4, (April 2022)"],"recId":"254638546","id":{"eki":["254638546"],"zdb":["1462966-5"],"issn":["1433-0415"]},"note":["Gesehen am 18.02.04","Ungezählte Beil.: Supplement"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Onkologe","subtitle":"Organ der Deutschen Krebsgesellschaft e.V.","title":"Der Onkologe"}],"disp":"Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib Empfehlungen einer interdisziplinären Expertengruppe = Prevention and management of cardiovascular diseases during treatment with the tyrosine kinase inhibitor nilotinib : recommendations of an interdisciplinary expert groupDer Onkologe","type":{"media":"Online-Ressource","bibl":"periodical"}}],"name":{"displayForm":["A. Kiani, P. Kuhlencordt, A. Hochhaus, H. Tesch, S. Saussele, P. Le Coutre"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib","subtitle":"Empfehlungen einer interdisziplinären Expertengruppe = Prevention and management of cardiovascular diseases during treatment with the tyrosine kinase inhibitor nilotinib : recommendations of an interdisciplinary expert group","title":"Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib"}],"physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a KIANIALEXAPRAEVENTIO2015 | ||